REG - Proteome Sciences - Result of AGM

Proteome SciencesAnnouncement

14/05/2026 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260514:nRSN3904Ea&default-theme=true

RNS Number : 3904E  Proteome Sciences PLC  14 May 2026

 

14 May 2026

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Result of Annual General Meeting (AGM)

 

The directors of Proteome Sciences are pleased to announce that at the
Company's AGM, held at 12.00 noon today, all resolutions were duly passed.

 

For information, the proxy votes received in relation to the resolutions were
as follows:

 

 RESOLUTION MATTER                                                               VOTES FOR       VOTES AGAINST   VOTES DISCRETIONARY  VOTES WITHHELD  VOTES

 TOTAL
 1.  To receive the report of the Directors and the audited Financial            147,914,675     2,800,402          539               71,282
 Statements of the Company for the year ended 31 December 2025.

                                                                                                                                                       150,786,898
 2. To receive and approve the Remuneration Report, excluding the remuneration     146,482,388   4,232,689       539                    71,282        150,786,898
 policy.
 3. To re-appoint Christopher Pearce as a Director of the Company.               147,740,986     2,890,589         0                  155,323         150,786,898
 4. To re-appoint Richard Dennis as a Director of the Company.                   147,704,238     2,947,337         0                  135,323         150,786,898
 5. To re-appoint Ian Pike as a Director of the Company.                         147,724,238       2,927,337       0                  135,323            150,786,898
 6. To re-appoint Ursula Ney as a Director of the Company.                         147,741,085      2,910,490      0                  135,323         150,786,898
 7. To re-appoint Martin Diggle as a Director of the Company.                    147,564,238       3,067,337       0                  155,323           150,786,898
 8. To re-appoint Cooper Parry Group Limited as auditors of the Company and to     147,796,267     2,890,439       0                  100,192         150,786,898
 authorise the Directors to determine the remuneration of the auditors.
 9. To authorise the Directors to exercise all or any of the powers of the       147,727,873       2,978,396       0                  80,629            150,786,898
 Company to allot equity securities up to an aggregate nominal amount of
 £1,168,966.13.
 10. To empower the Directors to dis-apply statutory pre-emption rights up to a    146,526,989      4,179,957      0                  79,952            150,786,898
 maximum aggregate nominal amount of £701,449.82.

 

 Proteome Sciences plc
 Christopher Pearce, Executive Chairman                                                  Tel: +44 (0) 20 7043 2116
 Dr. Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer

 SP Angel Corporate Finance LLP  (Nominated Adviser & Broker)
 David Hignell/Richard Morrison/Josh Ray  (Corporate Finance)   Tel: +44 (0) 20 3470 0470

 Vadim Alexandre (Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
with analysis using a range of depletion strategies in combination
with TMTcalibrator™ providing access to over 8,500 circulating plasma
proteins for the discovery of disease-related biomarkers. Chemoproteomics
using Solvent Shift  reveals the selectivity that drugs have to binding one
or more proteins in the sample proteome.  Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free biomarker
analyses in situations where standard ELISA assays are not available.

 

Further information on the Company can be found on its website at:
https://www.proteomics.com/ (https://www.proteomics.com/)

 

The Company's LEI is 213800Q62ICXANKU2986.

 

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAIMBTMTABBBF



            Copyright 2019 Regulatory News Service, all rights reserved